Health Chosun reports social media is flooded with health food ads borrowing the Wegovy name, even as the sellers see little profit recovery.
Recap by typeshit. Full story at 헬스조선.
Mounjaro became India's top-selling drug in 2025, and a Scroll investigation reports that pharmacies are handing it out without the prescription it requires.
The Sunrise health expert says unregulated peptide use can put people in hospital, and in the worst cases leave them needing a new liver.
Some people on weight loss drugs are testing lower doses, hoping for fewer side effects. ThePrint reports on the trend, which these users describe themselves.
Bell raises the question of muscle loss for people losing weight on a GLP-1 and notes it isn't medical advice, pointing viewers to their doctor.
Kral traces the shift from GLP-1 drugs to dual GIP/GLP-1 and GLP-1/glucagon agents, with triple agonists next in line.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Loading…